MICROTECH MED-B (02235) announced that its core product, the Equil patch insulin pump, has recently received approval from the National Medical Products Administration (NMPA) for pediatric and adolescent indications. This approval expands the product's applicable scope from the original "adult diabetic patients" to include children and adolescents aged 3-17 years, providing a new treatment option for millions of domestic pediatric and adolescent diabetes patients.

The clinical trial for this indication expansion was led by the Children's Hospital of Zhejiang University School of Medicine, in collaboration with six other leading national children's hospitals. The study fully demonstrated the efficacy and safety of CSII (Continuous Subcutaneous Insulin Infusion) in treating diabetes in children and adolescents.

The patch insulin pump is primarily designed for diabetic patients requiring insulin therapy. It enables precise and continuous insulin infusion, maximally mimicking the physiological insulin secretion pattern of the human body, helping diabetic patients better manage their blood glucose levels. Compared to traditional tube-type insulin pumps, this product offers advantages including more precise and safe delivery, more convenient and flexible wearing and usage, more economical semi-disposable design, enhanced privacy, and elimination of tube blockage and line entanglement issues.

This indication expansion demonstrates the company's strong independent research and development capabilities in diabetes monitoring, treatment, and management. It will further consolidate the company's leading position in the industry and help achieve strategic expansion of the product's market space.

Looking ahead, the company will continue to focus on global developments in diabetes monitoring, treatment, and management approaches, continuously driving technological and product innovation in related fields.